(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 April 2008 (17.04.2008)

PCT

(10) International Publication Number
WO 2008/045465 A1

(51) International Patent Classification:
A61K 31/20 (2006.01)

(21) International Application Number:
PCT/US2007/021631

(22) International Filing Date: 10 October 2007 (10.10.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/850,280 10 October 2006 (10.10.2006) US

(71) Applicant *(for all designated States except US)*: **RELIANT PHARMACEUTICALS, INC.** [US/US]; 110 Allen Road, Liberty Corner, NJ 07938 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **RONGEN, Roelof, M., L.** [NL/US]; 131 Fairmont Road East, Caliton, NJ 07830 (US). **SHALWITZ, Robert, A.** [US/US]; 2549 Bryden Road, Bexley, OH 43209 (US). **KLING, Douglas** [—/US]; 73 Alloway Road, Parsippany, NY (US). **DOYLE, Ralph, T., Jr.** [US/US]; 7 Berkshire Way, Milford, NJ 08848 (US).

(74) Agents: **BERMAN, Richard, J.** et al.; Arent Fox, PLLC, 1050 Connecticut Avenue N.W., Washington, DC 20036 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(54) **Title:** OMEGA-3 FATTY ACIDS AND DYSLIPIDEMIC AGENT FOR REDUCTION OF APO-B LEVELS

(57) **Abstract:** Methods of utilizing a combined administration or a unit dosage of a combination of a dyslipidemic agent and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypercholesterolemia, hypertriglyceridemia, mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.

WO 2008/045465 A1